Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Conditions
- Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaAcute Undifferentiated LeukemiaMixed Phenotype Acute LeukemiaRecurrent Acute Undifferentiated LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- Procedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Chest RadiographyProcedure: Echocardiography TestProcedure: Hematopoietic Cell TransplantationProcedure: Multigated Acquisition ScanProcedure: PheresisRadiation: Total-Body IrradiationProcedure: Biospecimen Collection
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06928662
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
- Conditions
- AMLRUNX1-RUNX1T1 Fusion Protein Expression
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 300
- Registration Number
- NCT06744504
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- AML
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT06744556
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
- Conditions
- Relapse/RecurrenceC-KIT MutationCore Binding Factor Acute Myeloid LeukemiaAML, ChildhoodRefractory AML
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 50
- Registration Number
- NCT06316960
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Kaifeng Children's Hospital, Kaifeng, Henan, China
🇨🇳Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- AML, ChildhoodAcute Myeloid Leukemia
- Interventions
- Drug: Recombinant Human Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 60
- Registration Number
- NCT06050941
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
- Conditions
- Acute Myeloid LeukemiaMyeloproliferative NeoplasmMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyDrug: Granulocyte Colony-Stimulating FactorProcedure: Multigated Acquisition Scan
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06034470
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- AMLAML with Mutated NPM1Hematologic MalignancyKMT2ArNPM1 MutationMLL RearrangementLeukemiaAcute Myeloid LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
- Interventions
- Biological: Granulocyte colony-stimulating factor
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT06001788
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Health - Bowyer Oncology Center, Los Angeles, California, United States
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Rady Children's Hospital-San Diego, San Diego, California, United States
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
- Conditions
- Core Binding Factor Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 88
- Registration Number
- NCT05404516
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.